Offering a way to settle Tirzepatide and nausea rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.
Topic summary
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported?
This is a generated summary. It shows the 9 most-liked posts from a topic of 123, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and it is worth remembering when people quote the trial.
I have written this out at length because the short version keeps being misread.
29 likes 3mo
I think the Tirzepatide and nausea question is answerable and has not been answered, which is a more optimistic position than most of this thread.
30 likes 3mo
a.adeyemi, post #19: Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it. That is one dataset and I would not build a rule on it. Go to post
What I want from this Tirzepatide and nausea thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it.
The version of Tirzepatide and nausea that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
31 likes 2mo
Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.
I have seen it go both ways, which is why I hedge.
27 likes 2mo
d.nilsen, post #94: The dual agonism is not a marketing framing — GIP receptor and GLP-1 receptor engagement are both demonstrable. What is genuinely unresolved is how much of the clinical effect the GIP limb contributes, because no trial decomposes it. Go to post
The dual agonism is not a marketing framing — GIP receptor and GLP-1 receptor engagement are both demonstrable. What is genuinely unresolved is how much of the clinical effect the GIP limb contributes, because no trial decomposes it.
Reading it back, the second half matters more than the first.
Read the full topic (123 posts)
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Tirzepatide storage and stability: what is published versus what is assumed
On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Asking about tirzepatide storage and stability directly,…
|
+17 | 21 | 17k | 12d |
|
What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version
Asking directly, because I could not find a straight answer: What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version A narrow question about GIP…
|
+48 | 52 | 609 | 10mo |
|
Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold?
Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? The question about Tirzepatide molecular mass that…
|
+7 | 11 | 281 | 6mo |
|
Tirzepatide molecular mass and the charge states you would expect on ESI
Tirzepatide molecular mass and the charge states you would expect on ESI Writing it up because I had to work it out twice and would rather nobody else did. Tirzepatide molecular mass keeps being re-asked here…
|
+36 | 40 | 44k | 11mo |
|
Tirzepatide's shorter half-life and its one practical consequence
On the subject in the title: Tirzepatide's shorter half-life and its one practical consequence Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…
|
+18 | 29 | 20k | 8mo |
Related topics — sharing the tags tirzepatide, SURMOUNT programme, effect size
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Vagal afferents and the gut-brain pathway
On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. Vagal afferents — I have the observation and I do not trust my interpretation of it, so I am…
|
+5 | 9 | 44k | 13mo |
|
The C-cell question: rodent findings and their human context
Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. The question about c-cell question that I actually want…
|
+41 | 45 | 24k | 12mo |
|
Journal club: FLOW and the renal composite, component by component
On the subject in the title: Journal club: FLOW and the renal composite, component by component Working notes rather than a conclusion. Reading FLOW ( N Engl J Med , 2024) for the population rather than the…
|
+84 | 91 | 18k | 2y |
|
Revisiting: Food effects on oral incretin absorption: what is documented
Revisiting: Food effects on oral incretin absorption: what is documented — setting out what I have, and where I think it stops being reliable. Food effects on oral incretin, from the point of view of someone…
|
+6 | 10 | 51k | 13mo |
|
Comparing the STEP programme populations: who was actually enrolled
Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers…
|
2 | 7.5k | 2mo |